Abstract: A housing fluidly coupled to an inlet tube received within a faucet delivery spout. The housing receives a flow modifying device (e.g., an aerator or a stream straightener), and includes a first baffle and a second baffle to provide a desired water flow to the flow modifying device.

Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to TNF-alpha, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.

Abstract: There is provided inter alia a composition comprising a TNF-alpha binding polypeptide and an IL-6R binding polypeptide.

Abstract: There are provided inter alia polypeptides capable of inhibiting IL-7 and/or L-TSLP binding to IL-7R (IL-7R), as well as to constructs and pharmaceutical compositions comprising these polypeptides.

Abstract: There is provided inter alia a composition comprising a TNF-alpha binding polypeptide and an IL-7R binding polypeptide.

Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-23, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1 comprises a sequence sharing 60% or greater sequence identity with SEQ ID NO: 1, CDR2 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 2 and CDR3 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 3.

Abstract: There are provided inter alia polypeptides capable of inhibiting IL-7 and/or L-TSLP binding to IL-7R (IL-7R), as well as to constructs and pharmaceutical compositions comprising these polypeptides.

Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-6R, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.

Abstract: There are provided inter alia polypeptides capable of inhibiting IL-7 and/or L-TSLP binding to IL-7R (IL-7R), as well as to constructs and pharmaceutical compositions comprising these polypeptides.

Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-23, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1 comprises a sequence sharing 60% or greater sequence identity with SEQ ID NO: 1, CDR2 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 2 and CDR3 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 3.

Abstract: Methods, devices and program products are provided for utilizing one or more processors to receive a request from a client device for a network responsive resource. The network responsive resource includes a substitute scripted component. The methods, devices and program products determine whether to implement load sharing based on utilization information indicative of a load and build the network responsive resource with a client-side scripted component as the substitute scripted component.

Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-23, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1 comprises a sequence sharing 60% or greater sequence identity with SEQ ID NO: 1, CDR2 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 2 and CDR3 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 3.

Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-6R, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.

Abstract: One embodiment provides a method, including: identifying an aspect present in media content, wherein the aspect is associated with a user; determining, using a processor, whether the aspect is compatible with user permissions delineated in a user profile associated with the user; and performing, responsive to determining that the aspect of the media content is not compatible with the user permissions, a remedial action. Other aspects are described and claimed.

Abstract: An approach is provided that detects when multiple apps are being displayed on a display screen with each of the apps having any number of user interface controls. A set of user interface controls is identified from the user interface controls being displayed. The identified set of user interface controls have an increased display preference. The identified set of user interface controls are enlarged on the display screen making such controls easier to read and select.

Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain comprising three complementarity determining regions (CDR1-CDR3) and four framework regions, wherein: (a) at least one lysine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue, and/or (b) at least one arginine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue; wherein the polypeptide has increased intestinal stability relative to a corresponding polypeptide not having said histidine substitutions.

Abstract: A system includes storage devices storing data units. Each data unit is stored on one of the storage devices. The system includes a processor, and a non-transitory computer-readable data storage medium storing computer-executable code. The processor executes the code to correlate workloads to the data units with respect to which of the workloads access which of the data units, and when the workloads access the data units. The processor executes the code to when the workloads access the data units and/or and on which of the storage devices the data units are stored, so that at given times the data units stored on a subset of the storage devices are not being accessed by any workload. The processor executes the code to, during each given time, power off the subset of the storage devices storing the data units that are not being accessed by any workload to conserve power.

Abstract: An approach is provided that detects when multiple apps are being displayed on a display screen with each of the apps having any number of user interface controls. A set of user interface controls is identified from the user interface controls being displayed. The identified set of user interface controls have an increased display preference. The identified set of user interface controls are enlarged on the display screen making such controls easier to read and select.

Abstract: There is provided inter alia a construct suitable for oral administration comprising a first polypeptide and a second polypeptide connected by a labile peptide linker, wherein the labile peptide linker is labile to one or more proteases present in the intestinal tract and wherein the first and second polypeptides are substantially resistant to said one or more proteases.

Abstract: There is provided a solid pharmaceutical composition for delivering by oral administration a pharmaceutically active binding polypeptide to a region of the intestinal tract comprising a compressed core, wherein the compressed core comprises a pharmaceutically active binding polypeptide and wherein the compressed core is coated with a pH sensitive enteric coating.